Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AB SCIEX Announces Biologics Initiative

Published: Friday, September 21, 2012
Last Updated: Friday, September 21, 2012
Bookmark and Share
Mass spectrometry leader’s BiologicsFocus programs address industry shift to biopharmaceuticals.

AB SCIEX has announced a global initiative focused on biologics. This new initiative is in response to the fundamental shift of the pharmaceutical industry into biopharmaceutical development.

AB SCIEX’s BiologicsFocus Initiative consists of four components: new product development; beta software evaluation program; one-on-one connections program; and forums for sharing the latest advancements in biologics across the scientific community.

The company revealed this initiative at the International Mass Spectrometry Conference (IMSC) in Japan.

The BiologicsFocus Initiative represents AB SCIEX’s open approach to producing comprehensive biologics solutions by involving scientists in industry and academia in the development of new tools.

AB SCIEX already has a proven track record with its TripleTOF technology for bio-therapeutics characterization.

The company is now taking the next important step to address an industry-wide need - the development of data analysis solutions to simplify and accelerate biologics development.

Forty-two percent of new drugs in drug development pipelines of pharmaceutical companies are based on biologics, according to survey results published earlier this year by EvaluatePharma, a market research firm.

Moreover, the development of biosimilars, or “generic” biologic drugs, is dramatically increasing globally in response to legislation enabling their licensure in the United States.

The trend is to transition away from the traditional model of drug development, which is based on small molecule analysis.

The promise of biopharmaceuticals is that pharmaceutical companies will be able to more rapidly develop more effective drugs with fewer side effects.

Recent advancements in technologies for large molecule analysis, such as protein characterization, have sped up the shift to bio-therapeutics.

AB SCIEX’s biologics initiative includes the following programs:

• BiologicsFocus Innovation - AB SCIEX is developing a suite of new products specifically for biologics. Because data analysis is considered to be a bottleneck for this type of analysis, the company is focusing on software development in the first phase of this initiative to eliminate this bottleneck.

• BiologicsFocus Eval - AB SCIEX is actively developing new biologics characterization software. To participate in a beta software evaluation program, go to www.absciex.com/biologics.

• BiologicsFocus Summits - AB SCIEX will host information-sharing forums or “summits” as special events that will bring together opinion leaders who are driving the evolution of biopharmaceuticals. This will also include an advisory network of scientists to provide input and feedback for ongoing product development.

• BiologicsFocus Connections - AB SCIEX will connect biologics researchers one-on-one with each other to cultivate new collaborations and advance this field of pharmaceutical science.

“We recognize biologics for its strategic importance to the pharmaceutical industry,” said Rainer Blair, President of AB SCIEX.

Blair continued, “AB SCIEX is well-positioned with our industry-leading hardware platforms and our unique combination of strengths in both large molecule characterization and pharmaceutical analysis. We are working closely with pharmaceutical scientists to develop and shape new software solutions that directly address the needs and requirements for the new frontier of drug discovery and development. We continue to be a trusted partner with pharmaceutical companies and academics worldwide.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCIEX and New Objective Announce Partnership
New nanospray sources to offer maximum sensitivity and robustness for NanoLC-MS.
Tuesday, June 02, 2015
AB SCIEX Wins New Product Innovation Award in Asia Pacific
The award recognizes the company’s continued innovation in the mass spectrometry industry and a number of new products introduced into the market in recent years.
Thursday, October 30, 2014
AB SCIEX, Dalton Pharma Services Announce ADC Partnership
Research collaboration aims to develop Antibody-Drug Conjugate analysis capabilities.
Wednesday, August 27, 2014
AB SCIEX to Present ESI-MS Workshop
The workshop will be presented at HPLC 2014.
Tuesday, April 22, 2014
Scientific News
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!